Loading
A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) is a phase 2 interventional study registered as NCT00880269 by Novartis Pharmaceuticals, with 59 participants recorded, started 2009-08 and reaching its primary completion in 2012-02. Interventions recorded: Panobinostat/LBH589. Conditions recorded: Refractory Leukemia, Acute Myelogenous Leukemia.
Linked to the drug Panobinostat because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Panobinostat, Novartis and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Novartis, Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Novartis and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/